Azathioprine

Evidence Level: L5

Predicted Indications: 7

Azathioprine

Pharmacist Assessment Report

Azathioprine: purine antimetabolite immunosuppressant → colobomatous microphthalmia-rhizomelic dysplasia syndrome

One-Sentence Summary

Azathioprine is an oral immunosuppressant (a purine antimetabolite) that is marketed in Australia. The TxGNN model predicts it may be relevant to colobomatous microphthalmia-rhizomelic dysplasia syndrome, an ultra-rare developmental malformation syndrome. No clinical trials and no publications in the data compiled for this report support this prediction, so it is a computational signal only.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	colobomatous microphthalmia-rhizomelic dysplasia syndrome
TxGNN Prediction Score	1.0000 (rounded to 4 decimals)
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data for azathioprine are not available in the data compiled for this report. Azathioprine is generally understood as a purine antimetabolite that suppresses lymphocyte proliferation and so dampens immune-mediated disease.

The predicted condition is a congenital developmental syndrome affecting the eye and skeleton. No immune-mediated or inflammatory driver is recognised that azathioprine’s action would plausibly target, so no mechanistic link can be established. The high TxGNN score reflects a network-based computational prediction only. It is not evidence of clinical benefit.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Australia Market Information

Azathioprine is currently marketed in Australia. The data compiled for this report record one valid single-ingredient product, an oral 50 mg tablet.

Safety Considerations

Drug Interactions: The interaction screen returned 100 recorded interactions. The main entries listed in the compiled data are:
- Moderate: mesalazine, balsalazide, olsalazine and sulfasalazine.
- Minor: zinc acetate, zinc gluconate and zinc sulfate.
- Level not classified: several other agents, including aspirin, omeprazole, pantoprazole, metformin, doxycycline, amphotericin B and morphine.

Warnings and contraindications were not captured in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for full safety information. Azathioprine is myelosuppressive and increases infection risk, so any use in a new, unstudied population needs careful consideration.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests on a model score alone. There are no supporting trials or publications, and no plausible immune-mediated mechanism links azathioprine to this developmental syndrome.

To proceed, the following is needed:

Published or registered studies that directly address colobomatous microphthalmia-rhizomelic dysplasia syndrome
A mechanistic rationale, supported by detailed mechanism-of-action data for azathioprine
Safety information from the TGA-approved PI, including warnings and contraindications, and a risk assessment for the target population
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.